With over 3000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
Our Process Technology Centers and WHO/USFDA/EMA/PDMA/NMPA-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 500 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements.
We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.
Regulatory Inspections of USFDA, PMDA, EMA and NMPA
Global Client QA Audits
Global Client EHS Audits
Successful EMA Audit Received at Porton’s Changshou Manufacturing Facility
2nd Successful USFDA Audit Received at Porton’s Changshou Manufacturing Facility
Awarded "Top 20 CRO Enterprises in China – 2019”
Launched Drug Product CDMO Unit [Porton Pharmaceutical Co., Ltd] to broaden our service offering to global pharmaceutical companies
Launched Exclusive Technology Partnership with Codexis Inc. to Harness the Power of Bio-catalysis for Pharmaceutical Synthesis
Porton Fine Chemicals Ltd. renamed Porton Pharma Solutions Ltd.
Launched Biologics CDMO Unit [Suzhou Porton Biologics Ltd] to bring cutting-edge development solutions for Gene and Cell Therapies production
Acquired J-star Research Inc. (NJ, USA) to provide high-efficiency, integrated process chemistry and cGMP manufacturing services to US customers
Launched New Global Corporate Headquarters & Process Technology Center in Chongqing, China
PMDA Audit Successfully Received at Porton’s Changshou Manufacturing Facility
Successfully Received USFDA Audit at Porton’s Changshou Manufacturing Facility
Porton (Stock code: 300363) was officially listed on the GEM (Growth Enterprise Market) of SZSE (Shenzhen Stock Exchange) on January 29, 2014
Awarded “Leading CMO 2012” by Life Science Magazine
Successfully Received 1st USFDA Audit with Zero 483 at Porton’s Chongqing Facility
Initiated Porton-up Program in Collaboration with Janssen (a unit of Johnson & Johnson)
Successfully Received 1st cGMP Quality Audit by a Global Pharmaceutical Company
Launched 1st Manufacturing Facility in Changshou [Chongqing, China]
Established Process R&D Centers in Chongqing & Chengdu, China
Porton Launches as a CMO with Global Ambitions
We are committed to helping our global customers efficiently develop high-impact and life-saving medicines, while sustainably and ethically building our business. Our social responsibility philosophy is Enabling public’s early access to good medicines; ensuring the health and well-being of our employees and communities; and emphasizing ethics and transparency in our dealings with all stakeholders.